Correspondence 0001437749-24-035779 from Autonomix Medical, Inc. (AMIX)
Autonomix Medical, Inc.
Date: Nov. 19, 2024 · CIK: 0001617867 · Accession: 0001437749-24-035779
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-282940
Letter
amix20241119c_corresp.htm
Ladenburg Thalmann & Co. Inc.
640 Fifth Avenue, 4th Floor
New York, New York 10019
November 19, 2024
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Re:
Autonomix Medical, Inc.
Registration Statement on Form S-1, as amended
File No: 333-282940
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules and Regulations of the U.S. Securities and Exchange Commission (the “Commission”) under the Securities Act of 1933, as amended (the “Securities Act”), Ladenburg Thalmann & Co. Inc., as representative of the underwriters for the proposed offering, hereby joins the request of Autonomix Medical, Inc. (the “Company”) that the effective date of the above-referenced Registration Statement be accelerated so that it will become effective at 5:30 p.m. Eastern Time on Thursday, November 21, 2024, or as soon thereafter as practicable.
Pursuant to Rule 460 of the General Rules and Regulations of the Commission under the Securities Act, please be advised that there will be distributed to each underwriter, dealer or agent, who is reasonably anticipated to participate in the distribution of the securities in this offering, as many copies of the preliminary prospectus as appears to be reasonable to secure adequate distribution of the preliminary prospectus.
The undersigned is aware of its obligations under the provisions of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended, including the delivery requirements contained in such Rule, in connection with the above-referenced issue.
Very truly yours,
Ladenburg Thalmann & Co. Inc.
Show Raw Text
CORRESP 1 filename1.htm amix20241119c_corresp.htm Ladenburg Thalmann & Co. Inc. 640 Fifth Avenue, 4th Floor New York, New York 10019 November 19, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Re: Autonomix Medical, Inc. Registration Statement on Form S-1, as amended File No: 333-282940 Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations of the U.S. Securities and Exchange Commission (the “Commission”) under the Securities Act of 1933, as amended (the “Securities Act”), Ladenburg Thalmann & Co. Inc., as representative of the underwriters for the proposed offering, hereby joins the request of Autonomix Medical, Inc. (the “Company”) that the effective date of the above-referenced Registration Statement be accelerated so that it will become effective at 5:30 p.m. Eastern Time on Thursday, November 21, 2024, or as soon thereafter as practicable. Pursuant to Rule 460 of the General Rules and Regulations of the Commission under the Securities Act, please be advised that there will be distributed to each underwriter, dealer or agent, who is reasonably anticipated to participate in the distribution of the securities in this offering, as many copies of the preliminary prospectus as appears to be reasonable to secure adequate distribution of the preliminary prospectus. The undersigned is aware of its obligations under the provisions of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended, including the delivery requirements contained in such Rule, in connection with the above-referenced issue. Very truly yours, Ladenburg Thalmann & Co. Inc. By: /s/ Nicholas Stergis Name: Nicholas Stergis Title: Managing Director, Head of Investment Banking cc: Leslie Marlow, Esq., Blank Rome LLP Patrick J. Egan, Esq., Blank Rome LLP